• 16 May 2024
• Admin
• News Article

FDA Approves Priority Review Status to PTC Therapeutics’ BLA for Upstaza

US FDA accepts and grants priority review status to PTC Therapeutics’ BLA for Upstaza to treat AADC deficiency

Overview

PTC Therapeutics, Inc. announced that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.

Words from CEO: PTC Therapeutics

• "We are excited to be one step closer to bringing an approved therapy to patients with AADC deficiency in the United States," said Matthew B. Klein, M.D., chief executive officer, PTC Therapeutics. 
• "The data collected to date continue to support the transformative benefit of Upstaza, this highly innovative gene therapy directly infused into the brain."

Upstaza

• Upstaza is a one-time gene replacement therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L–amino acid decarboxylase (AADC) deficiency with a severe phenotype. 
• It is a recombinant adeno-associated virus serotype 2 (AAV2)-based gene therapy, containing the human DDC gene. It is designed to correct the underlying genetic defect, by delivering a functioning DDC gene directly into the putamen, increasing the AADC enzyme and restoring dopamine production.

Efficacy and Safety of Upstaza

• The efficacy and safety profile of Upstaza has been demonstrated across clinical trials and compassionate use programmes. 
• The first patient was dosed in 2010. In clinical trials, Upstaza demonstrated transformational neurological improvements. 
• The most common side effects were initial insomnia, irritability and dyskinesia.

Upstaza Administration Procedure

• Administration of Upstaza occurs through a stereotactic surgical procedure, a minimally invasive neurosurgical procedure used for the treatment of a number of paediatric and adult neurological disorders. 
• The Upstaza administration procedure is performed by a qualified neurosurgeon in centres specialized in stereotactic neurosurgery.

AADC Deficiency

• AADC deficiency is a fatal, rare genetic disorder that typically causes severe disability and suffering from the first months of life, affecting every aspect of life – physical, mental and behavioural. 
• The suffering of children with AADC deficiency may be exacerbated by: episodes of distressing seizure-like oculogyric crises causing the eyes to roll up in the head, frequent vomiting, behavioural problems, and difficulty sleeping.

The lives of affected children are severely impacted and shortened. Ongoing physical, occupational and speech therapy, and interventions, including surgery, also are often required to manage potentially life-threatening complications such as infections, severe feeding and breathing problems.

PTC

PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.